

#

3D platform	A056
3D spatial imaging	A034

A


ADAR1	A066/PR009
Adipocytes, HSCDA, metabolism	B030
Adoptive cell therapy	B056/PR006, B063
Adrenergic	B035
Aging	A072
AhR/Nrf2 signaling	B057
Alisertib	A032
Allogeneic vaccine	B053
Anoikis Resistance	B026
Antibody-drug-conjugate	A042, B048, B068
Antitumor immunity	B053
ARID1A	A026, A048, A039/PR013
Artificial Intelligence	A018, B039, B042
ATM	B016, B061
Atovaquone	B061
AT-Rich Interaction Domain 4B	B051/PR014
Auranofin	A027

B

B cells	B064
Beta-1,3-N-acetylglucosaminyltransferase 5	B051/PR014
Bevacizumab	B058
Biomarker	A004, A036, A047, B059, B019
Biosensor	A038
BRCA / BRCA1 / BRCA2	A054, A072, B005, B016, B067
Brigatinib	A024

C

CA125	B043, B044
Caloric restriction	B057
Cancer	A009



Cancer immunology	B064
Cancer metabolism	A053
Cancer Stem-Like Cells	A071
Cancer-associated fibroblasts	A058/PR002
CancerStop	A016
Carnitine synthesis	B031
CAR-T	A064
CBX2	A032
CD24 monoclonal antibody	B052
Cell Migration	A072
Cell origin	A075
Chemoresistance / Chemotherapy Resistance	A012, A027, A032, A045, A006, B008/PR008, B069/PR007
Chimeric antigen receptor	B063
CHK1	A035
Chromatin	A079
Chromatin remodeling	B065
Chromosomal instability	B024
Chronic stress	A070/PR011, B021
Circadian disruption	B013
Circulating tumor cells	B041
Cisplatin and cisplatin-resistant Ovarian cancer	A012, A025
Claudin-4	B027
Clear cell ovarian cancer	A026, B037
Clinical trials	A014
Clofarabine	A050
Co-encapsulation	B028
Cofactors	A008
Combination therapy	A049/PR004, A004, B067, B028
Complement C3 inhibition	B036
Context-dependent signaling	B018
Copy number alterations	B022
CTPS1	A052/PR005
Cystathionine beta-synthase	B026
D	
Deconvolution	B006

DHODH inhibitor	A053
DHX9	A031
Diagnostic test	B059
Digital pathology	B039
Disease-free interval	B041
DNA damage	A050
DNA methylation	B010
DNA methyltransferase inhibitors (DNMTis)	B009
DNA repair	B031
Drug sensitivity	B005
Drug-resistant ovarian cancer	A029, A041

E

Early detection	A005, B014, B019, B038
Endometrial	A051
Endometriosis-associated ovarian cancer	A076
Endothelial ovarian cancer	B062
Epidemiology	A022
Epigenetic signature	B008/PR008
Epigenetics	A008, A069, B007, B012
Eprenetapopt	A046
Estrogen receptor alpha	A008
Extracellular vesicle and particle	B044

F

F2R/PAR1	A036
Factor-Xa inhibitor therapy	B029
FAK inhibitors	A022
Fallopian tube	A078, B032
Ferroptosis	A046
Fibrosis	A055/PR012
Folate receptor	A022
Functional impairment	A017
Fusokine	B060

G

Gene delivery	B011
---------------	------

Gene regulation	B012
Gene therapy	A033
Genomic instability	A031
Geriatric assessment	A017
Glycoproteins	A005
Graph theory	B017
GRP78	A060
Gynecologic cancer	B020

H

HER2	B048
Heterogeneity	B004
High-Grade Serous Ovarian Cancer (HGSOC / HGSC)	A011, A078, A020, A024, A028, A037, A047, A056, B002, B030, B032, B035, B039, B046, B067, B069/PR007, A063/PR003
Histopathology deep learning foundation models	B040
Homologous Recombination & Deficiency (HRD)	A019, A044, B001, B004, B046
HSF1	A040

I

ID8	B060
IL-12	B050
IL1 β (interleukin 1 β)	B060, B069/PR007
Immune Checkpoint Blockade / Inhibitors	A004, A039/PR013, A049/PR004, B058, B061
Immune Engineering	A055/PR012
Immune Infiltrate	A067
Immune microenvironment	A063/PR003
Immune tolerance	B057
Immunology	B055
Immunosuppression	B049
Immunotherapy	A045, B050
In vivo efficacy	B052
Inflammation	A055/PR012, B021
Innate Immunity	A069
Integrated stress response	A066/PR009
Interactive data visualization	A016

Interferon signaling	A066/PR009
Interleukins	A057/PR001, B060
Intraperitoneal administration	A033, B013
Iron oxide nanoparticles	B027

J

There were no keywords in this range.

K

KELIM	B042
KIF18A	B024
Knockdown	A012
Knowledge disparities	A014
KRAS	A039/PR013

L

L1CAM	A074
LATS1/2 kinases	B018
Ligand isomerism	A010
Lipid droplet-associated hydrolase	A061/PR010
LLM	A028
lncRNA	A013
Long-read DNA sequencing	B010
Lyophilization	A009

M

Machine learning	B014
Macrophage Disappearance Reaction (MDR)	A059
Macrophages	A061/PR010, A068
Maintenance therapy	A022
Malignant effusions	B036
MDSC	A070/PR011
Mesothelial clearance	B033
Metabolic dysfunction	B062
Metabolism	A072, B022, B037, B056/PR006, B064
Metabolites	B063
Metal Organic Frameworks	A013

Metastasis	B026
MHC compatibility	B053
Microdissection	B007
miR-195	A006
miRNA	A041, B014, B017
Mitochondria	A001, B022, B061
Mitosis	A042
Molecular imaging	B027
Monoclonal antibody	B068
Mouse Model	A071
mRNA	A068
MSC	A057/PR001
MUC16	B059
Mucinous ovarian cancer	A048
Multi-omics	B019
MYC	A040, A062

N

Nanoparticle	B011, B066
Neoantigen	B065
Neuroinflammation	B021
Neutrophil Extracellular Traps (NETs)	A059
Next-generation sequencing	B001
NF-kB	A025, B033
NK cells	B059, B062
NKAPL	A047
Non-invasive	B014
Notch	A027, A051
Novel Therapeutics	A030, A051, A052/PR005, A020
Nuclear CTSL	A050

O

Older ovarian cancer patients	A017
Omental milky spots	A034
Opportunistic salpingectomy	B045
Organoids	A078
Outcomes	A015

Ovarian cancer	A022, A034, A044, A052/PR005, A053, A002, A043, A065, A005, A015, A019, A061/PR010, A076, A071, B043, B044, B003/PR016, B024, B029, B041, B054, B013, B015, B025, B068, B020, B040, B045 B031, B014, B016, B058
Ovarian cancer model	A062
Ovarian cancer stem cells	A074
Ovarian clear cell carcinoma	A075
Oxidative stress	B061
P	
p53	A062
Paclitaxel	A031
PARP inhibition	A019, A020, A024, A038, A041, A043, A044, A054, A058/PR002, B009, B029
Patient advocates	A018, B034
PAX8	A011, A079
PD-L1	A060, B061
Peg cells, multi-omics, lineages	A078
Persister cells	B008/PR008
Phase 2 Trial	B036
Photodynamic therapy	B028
Platinum and platinum resistance	A010, A030, A035
Plk1	A042
POLQ	A037
Polyploid cancer cells	A023
Precision therapy	A036, A065
Predictive medicine	A056
Premalignancy	A077
Progesterone	A072, B032
Prognosis and prognostic biomarkers	A028, B005, B046
Punicalagin	A002

Q

There were no keywords in this range.

R


Recurrent ovarian cancer	A049/PR004, A004
Regional immunity	B066
Research priorities and strategy	A018, B034
ROR1	A060

S

Screening	B043
Semaphorin 7a	B049
Senescence	A072
Single-cell analysis	A023, B015
siRNA	A064
Solid Tumor	A064
Somatic evolution	B003/PR016
Somatic mutations	B001
Spatial Transcriptomics	A003, A076
Splicing	A068, B065
stakeholder consultation	B034
STAT3	B033
STIC	B038
Sting agonist	A069
Stress	B035
Stress protein	A060
Structural variants	B010
Subtypes	B006
Survivorship	A014, A015, B040

T

TGF- β	A011
T cells	A057/PR001, B056/PR006, B060
TAp63	A013
Targeted alpha therapy	A029
Targeted drug delivery	A033
Targeted therapy	A001, B011
Tertiary Lymphoid Structures	A004, B067
TGFBI	B054
Theranostics	A043



Therapeutic opportunities	A025
Therapeutic resistance	A007, B049
Therapeutic target	B054
Therapy	A045, B055
TIL	B056/PR006
TLR agonist	B066
TP53	A046, B003/PR016
Transcription	A079
Transcriptome analysis	B018
Transcriptomics	B007, B006
Translesion synthesis	A054
Transposable elements	A077, B012
Treatment	A040
Treatment resistance	A003, A067, B002
Tumor associated macrophages	B023
Tumor heterogeneity	B047/PR015
Tumor immune escape	B051/PR014
Tumor immunology	A058/PR002, A065, B047/PR015
Tumor microenvironment	A001, A003, A074, A068, A070/PR011, A067, B007, B023, B050, B030, B040, B055, A060
Tumor phagocytosis	B052
tumor stroma proportion	B042
Tumor-associated microbiome	B020
Tumor-infiltrating lymphocytes	B023
U	
Ultrasound	B038
V	
Vaccine	A009, A059, B060
Viral mimicry	A077
W	
Web-based clinical decision support	A016
Whole genome duplication	B004
WNT pathway	A030, B037

X

X-ray structure

A010

Y

There were no keywords in this range.

Z

ZBTB33 (Kaiso)

A025

ZNFX1

B009